ARCA BIOPHARMA ANNOUNCES SUBMISSION OF PATENT APPLICATON TO U.S. PATENT AND TRADEMARK OFFICE COVERING TREATMENT OF ATRIAL FIBRILLATION IN PATIENTS WITH HEART FAILURE Posted on May 13, 2019 by ARCA IT - Press Release, Uncategorized Gencaro AF HF Patent Submission 2019
ARCA BIOPHARMA ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Posted on May 8, 2019 by ARCA IT - Press Release, Uncategorized ARCA - 1Q19 Financial Results and Business Update
GENETIC-AF PHASE 2B TRIAL RESULTS PUBLISHED IN THE JOURNAL OF AMERICAN COLLEGE OF CARDIOLOGY: HEART FAILURE Posted on May 1, 2019 by ARCA IT - Press Release, Uncategorized GENETIC-AF Data - JACC April 2019
ARCA BIOPHARMA ANNOUNCES STEERING COMMITTEE OF LEADING INTERNATIONAL CARDIOLOGY AND ELECTROPHYSIOLOGY EXPERTS FOR PRECISION-AF PHASE 3 CLINICAL TRIAL Posted on April 23, 2019 by ARCA IT - Press Release, Uncategorized PRECISION-AF Steering Committee - FINAL
IDENTIFICATION OF PHOSPHODIESTEREASE 3A POLYMORPHISM WITH POTENTIAL TO INCREASE EFFECTIVENESS OF PDE3 INHIBITORS PUBLISHED IN THE JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Posted on March 18, 2019 by ARCA IT - Press Release, Uncategorized PDE3A PMx JACC - FINAL
DOSE RESPONSE OF BETA-BLOCKERS IN ADRENERGIC RECEPTOR POLYMORPHISM GENOTYPES PAPER PUBLISHED IN CIRCULATION: GENOMIC AND PRECISION MEDICINE Posted on March 6, 2019 by ARCA IT - Press Release, Uncategorized Beta Blocker Dose Response in AR Polymorphism Genotypes - Circ Genom Precis Med - FINAL
ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Posted on February 27, 2019 by ARCA IT - Press Release, Uncategorized ABIO - YE18 Financial Results and Business Update - FINAL
ARCA BIOPHARMA ANNOUNCES FDA AGREEMENT FOR A SINGLE PHASE 3 CLINICAL TRIAL TO SUPPORT APPROVAL FOR THE FIRST GENETICALLY-TARGETED CARDIOVASCULAR DRUG Posted on February 20, 2019 by ARCA IT - Press Release, Uncategorized Gencaro Phase 3 FDA SPA Agreement - FINAL
ARCA BIOPHARMA UPDATES SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL Posted on December 20, 2018 by ARCA IT - Press Release, Uncategorized Gencaro Phase 3 FDA SPA Amendment- FINAL
ARCA BIOPHARMA ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Posted on November 14, 2018 by ARCA IT - Press Release, Uncategorized ABIO - 3Q18 Financial Results and Business Update - FINAL